Q4 FY2026 · ended Jun 30, 2026 · Revenue $335,000, -15.8% YoY · Filed Sep 10, 2026
Pluri Inc. (PLUR) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q4 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $335,000 and a net loss of $5.9 million. Free cash flow was -$4.5 million. As of Jun 30, 2026 it held $3.5 million in cash and investments and $7.5 million in total debt.
Revenue
$335,000
-15.8% vs year-ago quarter
Net income
$-5.88M
+22.6% vs year-ago quarter
Operating cash flow
$-4.44M
+14.8% vs year-ago quarter
Free cash flow
$-4.47M
+24.7% vs year-ago quarter
EPS
$38.57
+4046.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
12.34M
+51.4% vs year-ago quarter
Net cash
$-3.95M
Q4 FY2026
Operating margin
-1655.5%
Q4 FY2026
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- PLUR (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- NV
- Headquarters
- Haifa
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1158780
- Former names
- PLURISTEM THERAPEUTICS INC (until Jul 13, 2022); PLURISTEM LIFE SYSTEMS INC (until Dec 28, 2007); AI SOFTWARE INC (until Jul 1, 2003)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q4 FY2026 Jun 30, 2026 |
Q3 FY2026 Mar 31, 2026 |
Q2 FY2026 Dec 31, 2025 |
Q1 FY2026 Sep 30, 2025 |
Q4 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $335,000 | $167,000 | $198,000 | $316,000 | $398,000 |
| Operating income | -$5.5M | -$6.5M | -$6.5M | -$6.3M | -$6.6M |
| Net income | -$5.9M | -$5.5M | -$6.5M | -$5.8M | -$7.6M |
| Diluted EPS | $38.57 | -$0.55 | -$0.71 | -$0.65 | -$0.98 |
| Operating cash flow | -$4.4M | -$4.5M | -$5.2M | -$5.4M | -$5.2M |
| Free cash flow | -$4.5M | -$4.6M | -$5.7M | -$5.5M | -$5.9M |
| Total assets | $24.9M | $26.1M | $30.6M | $33.7M | $38.7M |
| Stockholders' equity | -$23.0M | -$18.6M | -$14.6M | -$11.4M | -$6.8M |
| Cash and investments | $3.5M | $3.4M | $4.7M | $4.3M | $5.9M |
| Total debt | $7.5M | $6.2M | $6.9M | $6.7M | $6.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Oct 30, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Oct 20, 2026 | Oct 19, 2026 |
| 10-K | Annual report | Sep 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Aug 28, 2026 | Aug 26, 2026 |
| 8-K |
Current report
Other events
|
Aug 17, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Other events
|
Jul 14, 2026 | Jul 14, 2026 |
All 953 Pluri Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.